{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T09:14:09Z","timestamp":1793783649578,"version":"4.6.1"},"reference-count":53,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100020284","name":"Shire Pharmaceuticals Human Genetic Therapies Lexington","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020284","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ymgme.2024.108545","type":"journal-article","created":{"date-parts":[[2024,7,27]],"date-time":"2024-07-27T11:46:19Z","timestamp":1722080779000},"page":"108545","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA"],"prefix":"10.1016","volume":"143","author":[{"given":"Takashi","family":"Higuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohta","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fusao","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toya","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2024.108545_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3733","article-title":"\u03b1-galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2024.108545_bb0010","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1093\/jnen\/nlz139","article-title":"Fabry disease with concomitant Lewy body disease","volume":"79","author":"Tredici","year":"2020","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"10.1016\/j.ymgme.2024.108545_bb0015","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.39300","article-title":"Characterization of small fiber pathology in a mouse model of Fabry disease","volume":"7","author":"Hofmann","year":"2018","journal-title":"eLife"},{"key":"10.1016\/j.ymgme.2024.108545_bb0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.neulet.2015.01.084","article-title":"The Fabry disease-associated lipid Lyso-Gb3 enhances voltage-gated calcium currents in sensory neurons and causes pain","volume":"594","author":"Choi","year":"2015","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.ymgme.2024.108545_bb0025","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1212\/WNL.23.8.871","article-title":"Relief of pain of Fabry\u2019s disease by diphenylhydantoin","volume":"23","author":"Lockman","year":"1973","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2024.108545_bb0030","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jpeds.2004.01.051","article-title":"Fabry disease in childhood","volume":"144","author":"Desnick","year":"2004","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2024.108545_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/2326409816661351","article-title":"Small Fiber neuropathy in Fabry disease: a review of pathophysiology and treatment","volume":"4","author":"Politei","year":"2016","journal-title":"J. Inborn. Errors. Metab. Screen."},{"key":"10.1016\/j.ymgme.2024.108545_bb0040","doi-asserted-by":"crossref","first-page":"4168","DOI":"10.3390\/jcm10184168","article-title":"Review of mechanisms, pharmacological management, psychosocial implications, and holistic treatment of pain in Fabry disease","volume":"10","author":"Rajan","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0045","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/sj.mt.6300066","article-title":"Correction of the biochemical and functional deficits in Fabry mice following AAV8-mediated hepatic expression of \u03b1-galactosidase a","volume":"15","author":"Ziegler","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0050","doi-asserted-by":"crossref","first-page":"6","DOI":"10.5734\/JGM.2023.20.1.6","article-title":"Fabry disease: current treatment and future perspective","volume":"20","author":"Yoo","year":"2023","journal-title":"J. Genet. Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0055","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1136\/jmedgenet-2016-104178","article-title":"Oral pharmacological chaperone migalastat compared with enzyme replacement therapy in Fabry disease: 18-month results from the randomised phase III ATTRACT study","volume":"54","author":"Hughes","year":"2017","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108545_bb0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106981","article-title":"Patient reported quality of life and medication adherence in Fabry disease patients treated with migalastat: a prospective, multicenter study","volume":"138","author":"M\u00fcntze","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108545_bb0065","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.omtm.2020.08.012","article-title":"In vitro and in vivo amenability to Migalastat in Fabry disease","volume":"19","author":"Lenders","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2024.108545_bb0070","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1038\/s10038-019-0599-z","article-title":"Mutation spectrum of \u03b1-galactosidase gene in Japanese patients with Fabry disease","volume":"64","author":"Kobayashi","year":"2019","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2024.108545_bb0075","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s12883-016-0549-8","article-title":"Pain management strategies for neuropathic pain in Fabry disease-- a systematic review","volume":"16","author":"Schuller","year":"2016","journal-title":"BMC Neurol."},{"key":"10.1016\/j.ymgme.2024.108545_bb0080","first-page":"1993","article-title":"Fabry Disease","author":"Mehta","year":"2002","journal-title":"GeneReviews"},{"key":"10.1016\/j.ymgme.2024.108545_bb0085","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1089\/hum.2018.007","article-title":"Gene therapy in lipoprotein lipase deficiency: case report on the first patient treated with alipogene tiparvovec under daily practice conditions","volume":"29","author":"Kassner","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0090","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s40265-019-01162-5","article-title":"Onasemnogene Abeparvovec: first global approval","volume":"79","author":"Hoy","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ymgme.2024.108545_bb0095","series-title":"CADTH Issues in Emerging Health Technologies","first-page":"169","article-title":"Voretigene Neparvovec: An emerging gene therapy for the treatment of inherited blindness","author":"Patel","year":"2016"},{"key":"10.1016\/j.ymgme.2024.108545_bb0100","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(17)31868-8","article-title":"Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial","volume":"390","author":"Russell","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2024.108545_bb0105","doi-asserted-by":"crossref","DOI":"10.1126\/science.1233158","article-title":"Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy","volume":"341","author":"Biffi","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2024.108545_bb0110","doi-asserted-by":"crossref","first-page":"737","DOI":"10.15252\/emmm.201707573","article-title":"Gene therapy for ADA-SCID, the first marketing approval of an ex vivo gene therapy in Europe: paving the road for the next generation of advanced therapy medicinal products","volume":"9","author":"Aiuti","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0115","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1038\/nn.4593","article-title":"Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems","volume":"20","author":"Chan","year":"2017","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.ymgme.2024.108545_bb0120","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.ymthe.2019.02.013","article-title":"The GPI-linked protein LY6A drives AAV-PHP.B transport across the blood-brain barrier","volume":"27","author":"Hordeaux","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0125","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0225206","article-title":"Delivering genes across the blood-brain barrier: LY6A, a novel cellular receptor for AAV-PHP.B capsids","volume":"14","author":"Huang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2024.108545_bb0130","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1038\/s41467-020-15818-4","article-title":"Positron emission tomography imaging of novel AAV capsids maps rapid brain accumulation","volume":"11","author":"Seo","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymgme.2024.108545_bb0135","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/hgtb.2012.035","article-title":"Intrathecal shRNA-AAV9 inhibits target protein expression in the spinal cord and dorsal root ganglia of adult mice","volume":"23","author":"Hirai","year":"2012","journal-title":"Hum. Gene Ther. Methods."},{"key":"10.1016\/j.ymgme.2024.108545_bb0140","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.ymgme.2008.03.008","article-title":"Reduced alpha-gal a enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease","volume":"94","author":"Ohashi","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108545_bb0145","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/jgm.1566","article-title":"Minimum requirement of donor cells to reduce the glycolipid storage following bone marrow transplantation in a murine model of Fabry disease","volume":"13","author":"Yokoi","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0150","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s13023-023-02796-1","article-title":"Management of pain in Fabry disease in the UK clinical setting: consensus findings from an expert Delphi panel","volume":"18","author":"Stepien","year":"2023","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2024.108545_bb0155","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1097\/j.pain.0000000000002152","article-title":"Fabry disease pain: patient and preclinical parallels","volume":"162","author":"Burand","year":"2021","journal-title":"Pain"},{"key":"10.1016\/j.ymgme.2024.108545_bb0160","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108641","article-title":"Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of Fabry knockout male mice","volume":"9","author":"Lakom\u00e1","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.ymgme.2024.108545_bb0165","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.3390\/cells11111730","article-title":"Dysregulation of immune response mediators and pain-related ion channels is associated with pain-like behavior in the GLA KO mouse model of Fabry disease","volume":"11","author":"Spitzel","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymgme.2024.108545_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/17448069211033172","article-title":"Ion channels and pain in Fabry disease","volume":"17","author":"Weissmann","year":"2021","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ymgme.2024.108545_bb0175","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916663729","article-title":"Increased expression of Trpv1 in peripheral terminals mediates thermal nociception in Fabry disease mouse model","volume":"12","author":"Lakom\u00e1","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ymgme.2024.108545_bb0180","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s12979-023-00346-8","article-title":"Age-related neuroimmune signatures in dorsal root ganglia of a Fabry disease mouse model","volume":"20","author":"Choconta","year":"2023","journal-title":"Immun. Ageing"},{"key":"10.1016\/j.ymgme.2024.108545_bb0185","first-page":"432","article-title":"Diabetic neuropathic pain: physiopathology and treatment, world","volume":"6","author":"Schreiber","year":"2015","journal-title":"J. Diabetes"},{"key":"10.1016\/j.ymgme.2024.108545_bb0190","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/ddr.1201","article-title":"Enzyme specificity and tissue distribution of zenarestat, an aldose reductase inhibitor, and its relevance in the use of zenarestat as a therapeutic agent against diabetic neuropathy","volume":"54","author":"Takakura","year":"2001","journal-title":"T. Drug Development Res."},{"key":"10.1016\/j.ymgme.2024.108545_bb0195","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ymgme.2007.06.003","article-title":"Establishment and characterization of Fabry disease endothelial cells with extended lifespan","volume":"92","author":"Shen","year":"2007","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2024.108545_bb0200","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/jmg.20.4.309","article-title":"Involvement of dorsal root ganglia in Fabry\u2019s disease","volume":"20","author":"Gadoth","year":"1983","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.ymgme.2024.108545_bb0205","first-page":"431","article-title":"Intrathecal gene transfer by adeno-associated virus for pain","volume":"7","author":"Beutler","year":"2005","journal-title":"Curr. Opin. Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0210","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1002\/ar.23723","article-title":"Lentiviral vectors and adeno-associated virus vectors: useful tools for gene transfer in pain research","volume":"301","author":"Zheng","year":"2018","journal-title":"Anat. Rec. (Hoboken)."},{"key":"10.1016\/j.ymgme.2024.108545_bb0215","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.ymthe.2023.01.022","article-title":"Long-term reversal of chronic pain behavior in rodents through elevation of spinal agmatine","volume":"31","author":"Peterson","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/mt.2013.247","article-title":"Intrathecal AAV serotype 9-mediated delivery of shRNA against TRPV1 attenuates thermal hyperalgesia in a mouse model of peripheral nerve injury","volume":"22","author":"Hirai","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0225","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1194\/jlr.RA120000909","article-title":"Assessing the role of glycosphingolipids in the phenotype severity of Fabry disease mouse model","volume":"61","author":"Tabrizi","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.ymgme.2024.108545_bb0230","doi-asserted-by":"crossref","first-page":"389","DOI":"10.2119\/molmed.2015.00088","article-title":"Efficacy of enzyme and substrate reduction therapy with a novel antagonist of glucosylceramide synthase for Fabry disease","volume":"21","author":"Ashe","year":"2015","journal-title":"Mol. Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0235","doi-asserted-by":"crossref","DOI":"10.1177\/1744806916646379","article-title":"Comprehensive and differential long-term characterization of the alpha-galactosidase a deficient mouse model of Fabry disease focusing on the sensory system and pain development","volume":"12","author":"\u00dc\u00e7eyler","year":"2016","journal-title":"Mol. Pain"},{"key":"10.1016\/j.ymgme.2024.108545_bb0240","first-page":"1413","article-title":"Epidural and intrathecal drug delivery in rats and mice for experimental research: fundamental concepts","volume":"11","author":"Rahman","year":"2023","journal-title":"Tech. Precaut. Appl. Biomed."},{"key":"10.1016\/j.ymgme.2024.108545_bb0245","series-title":"UCSF office of Research Institutional Animal Care and Use Program","author":"Routes and Volumes of Administration in Mice","year":"2021"},{"key":"10.1016\/j.ymgme.2024.108545_bb0250","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1089\/hum.2018.015","article-title":"Severe toxicity in nonhuman primates and piglets following High-dose intravenous Administration of an Adeno-Associated virus vector expressing human SMN","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymgme.2024.108545_bb0255","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba9188","article-title":"MicroRNA-mediated inhibition of transgene expression reduces dorsal root ganglion toxicity by AAV","volume":"12","author":"Hordeaux","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2024.108545_bb0260","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing human alpha-L-Iduronidase in Rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2024.108545_bb0265","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology study of intra-cisterna magna adeno-associated virus 9 expressing Iduronate-2-sulfatase in Rhesus macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719224004293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T02:20:22Z","timestamp":1742437222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719224004293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":53,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S1096719224004293"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108545","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Restoration of peripheral neuropathy in Fabry mice via intrathecal administration of an adeno-associated virus vector encoding mGLA cDNA","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2024.108545","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108545"}}